Bank Holiday: Are Banks Open or Closed Today, February 12, for Guru Ravi Das Jayanti?

Banks in certain states will remain closed on February 12, 2025, for Guru Ravi Das Jayanti and local elections, as per news reports. However, digital banking services will continue to function as usual.

Details on Bank Holiday in Select States

Guru Ravi Das Jayanti is a significant observance in some regions of India, especially Himachal Pradesh, where banks will remain closed. In Aizawl, banks will also be closed for local elections, allowing citizens to vote.

The Delhi government has declared February 12 as a full holiday for government offices, replacing the earlier restricted holiday. However, the Reserve Bank of India has not officially updated its notification about the holiday status in Delhi.

Confirm Bank Holiday Details and Availability of Digital Services

As bank holidays vary by state, customers are advised to confirm with their local banks or refer to the official RBI website for a comprehensive list of holidays specific to their region.

In the states observing the holiday, banks will be closed, meaning services like cash withdrawals, deposits, and account-related transactions will not be available. However, digital banking services, including UPI, internet banking, and mobile banking, will remain operational.

Upcoming holidays in February

Banks will be closed in Manipur on February 15 in observance of Lui Ngai Ni, a festival celebrated by the Naga tribes of the state to mark the start of the seed-sowing season.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Check Why Market Fell Today? Trump Tariff, FII Selling Weighs on NSE, BSE On Feb 11, 2025

On February 11, 2025, The Sensex dropped by 1,018.20 points, or 1.32%, settling at 76,293.60, while the Nifty fell by 309.80 points, or 1.32%, closing at 23,071.80. A total of 516 shares rose, 3,330 shares declined, and 92 shares remained unchanged.

Top Gainers and Losers

The biggest losers on the Nifty included Apollo Hospitals, Eicher Motors, Shriram Finance, Coal India, and Bharat Electronics, while the gainers were Adani Enterprises, Trent, Bharti Airtel, and Grasim Industries.

Market activity saw a significant imbalance, with only 35 stocks hitting the upper circuit limit, while a staggering 305 stocks reached the lower circuit limit.

Weakness in Broader Markets and Sectoral Indices

All sectoral indices closed in the negative, with auto, consumer durables, capital goods, oil and gas, energy, FMCG, healthcare, power, PSU, and realty declining by 2%-3%.

The Nifty Midcap index fell by 3%, while the Smallcap index dropped by 3.5%.

Trump’s Tariff Plans Weigh on Global Markets

US President Donald Trump’s recent announcement to impose reciprocal tariffs on various imports, including steel, aluminum, cars, semiconductor chips, and pharmaceuticals, has sent ripples through global markets.

As Trump pushes forward with his plan, which involves increasing duties and ending exclusions on steel and aluminum tariffs, market participants are growing anxious about the potential fallout on international trade.

This heightened uncertainty has impacted the Indian stock markets, with sectors closely tied to global trade, like automobiles, metals, and pharmaceuticals, feeling the brunt.

FIIs Continue to Exit Indian Equities

Foreign Institutional Investors (FIIs) have been persistently selling Indian stocks, impacting overall market sentiment. On Monday alone, FIIs offloaded equities worth ₹2,463.72 crore.

According to NSDL data, they sold ₹78,027 crore in January and have now sold ₹85,841 crore worth of equities this year.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bharat Forge’s Shares in Focus; Subsidiary Signs MoU for Advanced Defence Technology

Bharat Forge’s KSSL and L3Harris Technologies sign a two-year MoU to collaborate on advanced defence solutions for India, focusing on C4ISR technologies and supporting tactical communication for the Indian Armed Forces, the company said in a press release on the stock exchanges.

KSSL-L3Harris MoU Details

Kalyani Strategic Systems Limited (KSSL), a subsidiary of Bharat Forge Limited, and L3Harris Technologies have signed a Memorandum of Understanding to strengthen collaboration in advanced defence technologies for India.

The two-year agreement will focus on delivering Command, Control, Communications, Intelligence, Surveillance, and Reconnaissance (C4ISR) solutions and supporting tactical communications for the Indian Armed Forces.

“This MOU sets the stage for future partnerships and opportunities in India, where the combined strengths of L3Harris and KSSL can contribute to bolstering national security,” said Dave Johnson, Vice President, International, L3Harris.

The collaboration aims to expedite the delivery of advanced tactical radios and equipment to the Indian military.

The focus of this partnership is on the Indian market, but the MOU also aims to build resilient supply chains for global defence obligations. L3Harris, with more than 21 years in India, provides advanced technologies, including tactical radios, and partners with the Airport Authority of India to enhance telecommunications infrastructure at airports.

KSSL, backed by Bharat Forge, has developed indigenous defence products and continues to expand its global footprint with artillery systems, mobility solutions, and munitions.

Share Price Performance

Bharat Forge Limited’s share price stood at ₹1,124.95 at 1:00 PM on the NSE, reflecting a decrease of ₹9.85 or 0.87% from the previous close. The stock opened at ₹1,133.90 and reached a high of ₹1,134.75 during the trading session. The low point for the day was ₹1,114.15.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

USD/INR: Rupee Gains Close to 1% Against Dollar, Hits 87 Mark Following RBI Intervention

The Indian rupee experienced a sharp rally, surging nearly 1% against the US dollar on Tuesday, its most significant rise in over two years. At 12:30 PM, the USD/INR spot rate was 86.88, trading 0.68% lower.

The surge, which took the rupee back above the 87 mark for the first time since January 31, was largely attributed to the Reserve Bank of India’s (RBI) intervention, as per news reports.

Strong Dollar Index and Weak Asian Peers

This rebound comes even as other Asian currencies have weakened, and the dollar index held steady at 108.3. The rupee has faced downward pressure in 2025, impacted by concerns about trade wars, foreign stock market sales, and changes in RBI policies.

On Monday, the rupee had dropped 45 paise, nearing the 88 per US dollar mark, pressured by the strength of the American currency and tariff concerns. However, it later recovered, gaining 5 paise to close at 87.45, thanks to intervention by the RBI.

Oil Prices Edge Higher Amid Russian Production Shortfall

Oil prices continued to rise on Tuesday, supported by a report showing that Russian oil production fell short of its quota, as well as concerns over potential supply disruptions.

However, the gains were capped by fears that escalating trade tariffs could slow global economic growth.

Brent crude futures rose by 0.32% to $76.11 per barrel, while US West Texas Intermediate crude increased by 0.26% to $72.51. Both contracts had posted gains of nearly 2% in the previous session, after three consecutive weeks of losses.

Disruptions in Russian oil shipments to major crude importers like China and India, caused by US sanctions on tankers, producers, and insurers, have heightened concerns over supply.

Additionally, the re-imposition of US sanctions targeting Iranian oil exports to China has further added to supply worries.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Kalpataru Ventures into Major Mumbai Redevelopment Projects with ₹2,000 Crore Potential

Realty developer Kalpataru has secured agreements to redevelop two large housing societies in Mumbai’s Chembur and Goregaon, covering 7.5 acres of land,as per news reports.

With a combined development potential of over 1.5 million sq ft, these projects are projected to generate revenue exceeding ₹2,000 crore and are expected to be completed within 42 months, as per ET report.

Kalpataru’s ₹2,000 Crore Projects in Chembur, Goregaon

Kalpataru, a prominent real estate developer, has entered into redevelopment agreements for two significant housing societies in Mumbai’s Chembur and Goregaon, spanning a total of 7.5 acres.

These projects will involve the development of more than 1.5 million square feet of real estate, with expected revenues exceeding ₹2,000 crore. The redevelopment is set to be completed within 42 months from the commencement of construction.

The Suman Co-operative Housing Society, located in Suman Nagar on five acres, is the first of the two projects. It consists of 10 residential buildings, and Kalpataru plans to construct six new towers, offering over 4.2 lakh square feet of carpet area.

A total of 350 apartments will be available for sale in this redevelopment. The second project, located in Goregaon near the Link Road and Bangur Nagar Metro station, covers 2.5 acres and includes the redevelopment of eight residential buildings.

The Goregaon project will feature three towers with 18 habitable floors, with Kalpataru’s share of the carpet area being nearly 2 lakh square feet, comprising 200 apartments for sale.

Government Policy Eases Redevelopment Costs in Mumbai

As Mumbai faces a shortage of vacant land, the redevelopment of old housing societies has become a crucial aspect of the city’s real estate market.

In 2023, the Maharashtra government announced that housing society members undergoing redevelopment would no longer have to pay stamp duty on the allotted permanent accommodation.

Instead, a nominal ₹100 stamp duty is required from the individual members, while the principal agreement between the developer and the housing society is subject to the usual conveyance charges.

This policy, combined with the strong real estate market, has significantly contributed to the ongoing redevelopment of older housing societies in the region.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Mankind Pharma Shares in Focus; Sells Stake in Mahananda Spa to Chalet Hotels

Mankind Pharma has approved the sale of its entire stake in Mahananda Spa and Resorts Pvt Ltd to Chalet Hotels for ₹5,300 Million. The transaction is expected to be completed by February 28, 2025, with proceeds used to reduce debt, the company said in a press release on the stock exchange.

Details of Mankind Pharma’s Sale of Mahananda Spa

Mankind Pharma Limited has announced the sale of its entire stake in Mahananda Spa and Resorts Private Limited (Mahananda), a wholly owned subsidiary, to Chalet Hotels Limited. The deal was approved by the Board-appointed Committee of Independent Directors on February 10, 2025.

The total consideration for the sale is ₹5300 million, subject to closing adjustments, and the sale is expected to be completed by February 28, 2025. The proceeds will be utilised to retire part of Mankind Pharma’s debts.

For the financial year ending March 31, 2024, Mahananda contributed ₹7,433.24 lakhs (0.72%) to the turnover and ₹40,135.92 lakhs (4.29%) to the net worth of the company.

Chalet Hotels, part of the K Raheja Corp Group, is a prominent hotel chain and will acquire Mahananda as part of this transaction. This sale does not fall within related-party transactions and will not impact the Scheme of Arrangement.

Mankind Pharma Q3FY25 Results

Mankind Pharma’s consolidated profit after tax (PAT) for the third quarter of FY25 fell by 16.5% year-on-year (Y-o-Y), totalling ₹385 crore compared to ₹460 crore in Q3FY24. Despite the decline in PAT, the company achieved a significant 24% increase in revenue from operations, reaching ₹3,230 crore, up from ₹2,607 crore in the same period last year.

The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) for the quarter stood at ₹833 crore, with an adjusted EBITDA margin of 27.7%, compared to ₹611 crore and 23.4% in the corresponding period of FY24.

Mankind’s domestic business saw 16% growth in Q3FY25, reaching ₹2,773 crore in revenue. The company also experienced notable growth in its consumer healthcare segment, which grew 30% year-on-year.

Share Price Performance

Mankind Pharma Limited’s stock saw a decline of 1.61% as of 11:32 AM on the NSE, with the price dropping by ₹40.30 to ₹2,461.75. The stock opened at ₹2,525 and reached a high of ₹2,557.45 before dropping to a low of ₹2,450.

Explore the power of a Demat account to streamline your investments. Get started now and manage your stocks and securities effortlessly on a trusted platform!

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Lupin Shares in Focus; Receives US FDA Approval for Generic Ipratropium Bromide Nasal Spray

Lupin announced that it has received approval from the US FDA for its Abbreviated New Drug Application for Ipratropium Bromide Nasal Spray, a generic equivalent of Atrovent Nasal Spray, with estimated annual sales of USD 22 million.

USFA Approval Details

Lupin Limited, a global pharmaceutical leader, announced today that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 mcg/spray).

This approval allows Lupin to market a generic version of Atrovent Nasal Spray, 0.03%, developed by Boehringer Ingelheim Pharmaceuticals, Inc.

Product Details and Lupin’s Global Presence in Pharma Manufacturing

The product will be manufactured at Lupin’s Pithampur facility in India. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%, is indicated for the symptomatic relief of rhinorrhea associated with both allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

According to IQVIA MAT December 2024, the reference listed drug (RLD), Atrovent, had estimated annual sales of USD 22 million in the US.

About Lupin

Lupin Limited is headquartered in Mumbai, India, and distributes products in over 100 markets worldwide. The company focuses on generic formulations, biotechnology products, active pharmaceutical ingredients, and complex generics.

Lupin has established a strong presence in the US and India, particularly in therapeutic areas like respiratory, cardiovascular, anti-diabetic, and anti-infective, among others. It has 15 manufacturing sites and 7 research centers globally, along with a workforce of over 22,000 professionals.

Share Price Performance

Lupin’s share price is trading at ₹2,094.70 at 10:35 AM on the NSE, marking a decline of ₹74.70 or 3.44% from its previous close of ₹2,169.40. The stock opened at ₹2,178.60 and reached a high of ₹2,178.60, before dropping to a low of ₹2,094.50.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Rail Vikas Nigam Shares in Focus; Secures ₹335 Crore Kavach Project

Rail Vikas Nigam Ltd (RVNL) has emerged as the lowest bidder for a ₹335.4 crore Kavach contract from South Western Railway. Despite this win, RVNL reported a 27% YoY decline in net profit for Q3 FY25.

Project Details

Rail Vikas Nigam Ltd (RVNL), a state-owned company, announced on Monday (February 10) that it has emerged as the lowest bidder (L1) for a ₹335.4 crore contract from South Western Railway.

The contract involves the survey, design, supply, installation, testing, and commissioning of Kavach equipment, along with other related works across 790 route km (RKM) in the Hubballi and Mysuru divisions.

In a regulatory filing, RVNL confirmed its position as the L1 bidder, stating that the work will enhance railway safety by implementing the Kavach system.

Kavach is an automatic train protection (ATP) system designed to prevent train collisions and regulate speed, significantly improving railway safety. Despite this new contract win, shares of RVNL closed at ₹381.30, down by ₹14.05 or 3.55% on the BSE.

RVNL Q3 FY25 Financial Performance

For Q3 FY25, RVNL reported a 27% year-on-year (YoY) decline in net profit, dropping to ₹286.9 crore from ₹394.3 crore in the same period last year.

This decrease was mainly due to reduced operating margins and lower earnings. Revenue from operations also declined by 1.2% YoY to ₹4,855 crore, compared to ₹4,914.3 crore in Q2 FY24. EBITDA fell by 9% to ₹271.5 crore, and margins narrowed to 5.6% from 6% in the previous year, indicating mounting operational challenges.

However, RVNL did show improvement on a quarter-on-quarter (QoQ) basis, with profits rising by 28.1% and revenue increasing by 19.2% in Q2 FY25, suggesting a sequential recovery.

Share Price Performance

Rail Vikas Nigam’s share price traded at ₹370.35 at 10:10 AM on the NSE, showing a decline of ₹11.10 or 2.91% from its previous close of ₹381.45. The stock opened at ₹383.00 and reached a high of ₹385.75, but later dropped to a low of ₹370.15.

The stock price of Rail Vikas Nigam Limited extended its previous two sessions of losses, falling by nearly 2.5% today.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Nykaa’s Parent FSN E-commerce Shares in Focus; Reports 51% Rise in Q3 FY25 Net Profit

FSN E-Commerce Ventures, the parent company of Nykaa, posted a strong performance for Q3 FY25, with a significant 51% year-on-year increase in net profit and a solid growth in consolidated revenue. FSN E-Commerce Ventures share price traded 1.82% higher at ₹172.52 at 9:45 AM on the NSE.

Q3 FY25 Earnings Highlights

FSN E-Commerce Ventures, the parent company of beauty and fashion brand Nykaa, reported a 51% year-on-year (YoY) increase in its net profit, reaching ₹26.4 crore for the third quarter ended December 31 (Q3 FY25), compared to ₹17.5 crore in the same period last year.

The company had posted a profit of ₹13 crore in the previous quarter, according to regulatory filings.

Nykaa’s consolidated revenue from operations grew by 27% YoY, reaching ₹2,267 crore, up from ₹1,789 crore a year ago and ₹1,875 crore in Q2 FY25. This revenue growth was in line with the company’s guidance, which expected growth to be “higher than mid-twenties” as per its quarterly revenue update on January 5.

Q3 FY25 Revenue and Expense Overview

The revenue boost was primarily driven by Nykaa’s core beauty segment, which saw accelerated growth compared to previous quarters. The company also anticipated a gross merchandise value (GMV) growth in the low thirties for this vertical, fuelled by strong momentum across various channels, including its e-commerce platform, retail stores, owned brands, and eB2B distribution.

Nykaa’s Share Price Performance

FSN E-Commerce Ventures share price opened at ₹170.53, reaching a high of ₹174.52 and a low of ₹168.12. The share broke its three-session losing streak today, with the stock having dropped nearly 3% in the last three sessions.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

ITC Shares in Focus; Dividend of ₹6.5 Record Date Set for Tomorrow, February 12

ITC, the tobacco-to-hotels conglomerate has declared an interim dividend of ₹6.50 per share of ₹1 each for FY25, with the record date for determining eligible members set for February 12, 2025.

ITC Dividend Payout History

ITC has declared a total of 29 dividends since July 3, 2001. Below is a table detailing the company’s recent dividend payouts.

Announcement Date Ex-Dividend Date Dividend Type Dividend (₹)
06 February, 2025 12 February, 2025 Interim ₹6.50
23 May, 2024 04 June, 2024 Final ₹7.50
29 January, 2024 08 February, 2024 Interim ₹6.25
18 May, 2023 30 May, 2023 Final ₹6.75
19 May, 2023 30 May, 2023 Special ₹2.75
03 February, 2023 15 February, 2023 Interim ₹6.00
18 May, 2022 26 May, 2022 Final ₹6.25
03 February, 2022 14 February, 2022 Interim ₹5.25
01 June, 2021 10 June, 2021 Final ₹5.75

ITC Q3 FY25 Results

ITC reported a 1.2% increase in net profit for Q3 FY25, reaching ₹5,638 crore compared to ₹5,572 crore in Q3 FY24.Net revenue for the quarter grew by 8.6% year-on-year, totaling ₹17,726 crore.

The company’s FMCG Others business showed a 4% YoY revenue growth, reaching ₹5,418 crore for Q3 FY25, despite subdued demand conditions.

Revenue from the Cigarettes segment increased by 7.8% YoY to ₹8,136 crore, with an 8.1% growth after adjusting for excise duty and NCCD, primarily driven by volume growth. The Agri Business segment saw a 9.7% YoY revenue increase to ₹3,351 crore, supported by strong growth in Leaf Tobacco and value-added Agri products.

The Paperboards, Paper, and Packaging segment faced challenges from low-priced Chinese and Indonesian imports, weak domestic demand, and a sharp rise in wood prices. Segment revenue for Q3 FY25 was ₹2,144 crore, marking a 3.1% YoY increase.

The Hotels business experienced a robust 14.6% YoY revenue growth, reaching ₹922 crore. The business was demerged into ITC Hotels Limited (ITCHL) effective 1 January 2025, with ITCHL shares being listed on the stock exchanges on 29 January 2025.

Share Price Performance

ITC share price opened at ₹428.80, slightly higher than its previous close of ₹427.20. The stock has touched a high of ₹430.55 and a low of ₹427.70, showing a modest movement. Currently, it is up by ₹3.10, reflecting a 0.73% increase.

Discover the power of efficient trading with our trading app. Download the Angel One app today and begin your journey to success!

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a pe₹onal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.